 The China National Medical Products Administration NMPA has approved Zai Lab Limiteds NASDAQ: ZLAB Nuzyra omadacycline, a novel antibiotic with both oral and intravenous IV formulations. The approval covers the treatment of community-acquired bacterial pneumonia CABP and acute bacterial skin and skin structure infections ABSSSI. 